Sandoz Industrial Products GmbH will be renamed Corden BioChem and will be associated with the CordenPharma Group, ICIG’s pharmaceutical platform.
On April 1, 2016, International Chemical Investors Group (ICIG) announced the completion of its acquisition of Sandoz Industrial Products GmbH, a Frankfurt-Höchst-based manufacturer of enzyme fermentation products and intermediates for the pharmaceutical industry, from Novartis Group.
Sandoz Industrial Products will be renamed Corden BioChem GmbH and will be associated with the CordenPharma Group, the pharmaceutical platform of ICIG. Corden BioChem will be complementary to ICIG’s pharma activities as well as to its fine chemicals activities within the WeylChem Group. According to a press announcement, ICIG is focused on the development of Corden BioChem with the enzymatic 7-ACA businesses for antibiotics applications at the Höchst site as well as the CordenPharma Latina site in Italy.
Source: ICIG
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.